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Background: CD28neg T cells, which display functional characteristic of oligoclonally expanded cytotoxic memory T
lymphocytes, are believed to be pathologically relevant in rheumatoid arthritis manifestation. The CD28 co-stimulation
blockade by abatacept can prevent the generation of CD28neg T-cell populations in these patients.
Methods: Samples were obtained before and after 12 months of abatacept therapy. T-cell phenotype and T-cell
receptor diversity were evaluated by flow cytometry and complementarity-determining region-3 spectratyping,
respectively, while telomerase reverse-transcriptase gene level was measured by real-time PCR.
Results: Abatacept induces a decrease of the percentage and number of CD4+CD28neg T cells and a reduction of
T-cell repertoire restrictions; these features are directly correlated. Thymic output and telomerase activity are not
modified by the therapy.
Conclusions: Abatacept-induced decrease of peripheral T-cell repertoire restrictions can be due to a reduced generation
of senescent, chronically stimulated CD4+CD28neg T cells.
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Several changes of the T-cell compartment have been
described in rheumatoid arthritis (RA) patients, which
include, in some patients, an increased number of T cells
lacking the CD28 costimulatory molecule, which are
clonally expanded [1]. The emergence of CD28neg T cells
has been attributed to repeated antigenic stimulation
induced by chronic inflammation or latent infections,
especially by cytomegalovirus [2,3]. These clonal T lympho-
cytes, which display functional characteristic of cytotoxic
memory T cells and are resistant to apoptosis, are believed
to be pathologically relevant in RA development [4], and
accordingly, their increase has been related to worse
prognosis and extra-articular manifestations [5].
Abatacept (ABA) is a fusion protein (CTLA4-Ig) that
has proven useful in the treatment of RA; its CTLA4
portion binds CD80 and CD86, the CD28 ligands, on
antigen-presenting cells, and competing with the engage-
ment of CD28 on T cells, the drug influences the subse-
quent T-cell activation [6]. Initial studies, performed in* Correspondence: limberti@yahoo.it
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unless otherwise stated.mice treated with CTLA4-Ig, showed that the treatment
resulted in an inhibition of memory response and in a
decrease of effector/memory populations [7]. In RA
patients, ABA induces a significant down-regulation of
T-cell effector subsets including Th1, Th2 and Th17
populations [8]. Furthermore, in treated patients, we have
demonstrated a reduction of circulating CD4+CD28neg
and CD8+CD28neg T cells, which was correlated with an
improvement of RA disease activity, suggesting that the
co-stimulation blockade can prevent the generation of
CD28neg T-cell populations [9,10].
Since CD28neg T cells are oligoclonally expanded lym-
phocytes [1], here we investigated whether their decrease
during ABA treatment was accompanied by a reduction
of T-cell repertoire restrictions. Moreover, we studied
whether thymic output and apoptosis modifications were
involved in these changes. For this latter purpose, since
telomerase reverse transcriptase (TERT) insufficiency
resulting in excessive T-cell apoptosis [11] has been
described in RA patients, we evaluated TERT activity
before and after therapy with ABA.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Patients
From March 2008 to December 2011, 44 consecutive
RA patients treated with intravenous ABA for at least
12 months were enrolled (Table 1).
The study was approved by the Spedali Civili of Brescia
Ethical Committee (approval n. 863/fg), and patients’
written consent, according to the Declaration of Helsinki,
was obtained. Patient clinical evaluation followed the
Disease Activity Score 28, based on C-reactive protein
(DAS28-CRP) [11,12]. Blood samples were obtained at the
start of ABA treatment (T0) and after 12 months of
therapy (T12). Results were compared with those of 16
age- (median: 49 years, interquartile range (IQR): 39-53),
and gender-matched healthy controls (HC), which were
recruited among laboratory personnel.
T-cell subset identification, TCR spectratyping analysis,
and TERT quantification
T-cell subset quantification was performed by flow cyto-
metry as previously described [9]; recent T emigrants (RTE)
and highly antigen-experienced T cells were lymphocytes
with CD4+CD45RA+CD31+ and CD4+CD45RA+CCR7−
phenotypes.Table 1 Main clinical features of enrolled RA patients
Total cohort o
(n = 44)
Sex (male/female) 6/38
Age, years (range) 54 (47-60)
Rheumatoid factor positivity 33 (75%)
AntiCCPc positivity 36 (82%)
Disease duration, years (range) 8 (4-13)
Smokers 14 (32%)
Comorbidities:
Arterial hypertension 17
Diabetes mellitus 4
Cardio-vascular events 4
Number of previous DMARDsd 3 (2-5)
Previous biological agents:
Infliximab 21
Etanercept 27
Adalimumab 28
Rituximab 9
Tocilizumab 4
Anakinra 6
DAS28-CRP at baseline (range) 5.10 (4.40-5.97)
Median dosage of methotrexate at baseline (range) 12.5 (6.25-15)
Median number of DMARDs at baseline (range) 1 (1-1)
aTCRBV: T-cell receptor variable beta; bTERT: telomerase reverse transcriptase; cAnti-
anti-rheumatic drugs.T-cell receptor (TCR) repertoire was analyzed by
complementarity-determining region-3 (CDR3) spectra-
typing after TCR beta variable (TCRBV) gene multiplex
PCRs that allow the detection of 23 functional TCRBV
families starting from 500 ng of total RNA extracted
from at least 2x106 peripheral blood mononuclear cells
(PBMC) [13,14]. The length distribution of fluorescent-
labelled PCR products was analyzed on an ABI 3130
analyzer (Applied Biosystems). Distribution of fragment
lengths, number of detectable peaks per TCRBV elem-
ent, and area under the curve were calculated by Peak
Scanner software version 1.0 (Applied Biosystems). Data
were analyzed and reported in three different ways; in
the first two, TCRBV repertoires were globally analyzed
while in the third, TCRBV perturbations were evaluated
at the single patient level. Therefore, proportions of
TCRBV families of all patients were grouped depending to
the “normal” (≥7 peaks, Gaussian distribution), “shifted”
(≥7 peaks, deviation from Gaussian distribution), “re-
stricted” (<7 peaks prominent deviation from Gaussian
distribution), “mono/oligoclonal” (1 or 2 dominant peaks)
distribution of the CDR3 region [15]. TCRBV perturba-
tions were also evaluated with the generalized Hamming
distance method [14] by “subtracting” from the CDR3f patients RA patients evaluated for TCRBVa
repertoire and TERTb (n = 17)
p
4/13 0.300
57 (48-60) 0.412
12 (70%) 0.979
15 (88%) 0.825
4 (2-7) 0.001
7 (41%) 0.697
4 0.416
1 0.223
0 0.478
2 (2-3) 0.001
5 0.313
8 0.256
9 0.635
1 0.321
3 0.623
2 0.999
5.06 (4.41-5.46) 0.185
15 (10-15) 0.042
1 (1-1) 0.022
CCP: anti-cyclic citrullinated peptide antibodies; dDMARDs: disease modifying
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average Gaussian-like CDR3 length distribution obtained
by analyzing the TCR repertoire of a “reference group”
composed of 8 HC and then by calculating the mean
percentage of restrictions. Finally, for each patient, each
TCRBV perturbation observed at T0 was subtracted from
that found at T12.
TERT was measured by real-time PCR in PBMC,
stimulated for 4 days in 24-well plate coated overnight
with 1 μl/ml of anti-CD3 monoclonal antibody diluted
in PBS. Primers and probes were from Applied Bio-
systems (TERT: Hs00972656_m1, GUSB:Hs99999908_m1);
beta-D-glucuronidase were used as housekeeping gene and
pooled cells of 10 HC as calibrator. Results were calculated
with the ΔΔCt method and reported as normalization
ratio (NR).Statistical analysis
Data were expressed as median and IQR. The compari-
son between quantitative variables describing cell sub-
populations in different groups was analyzed with the
Mann-Whitney test, while the Wilcoxon signed-rank
test was applied to assess variation within paired groups.
In the case of TCRBV perturbations, comparisons were
performed by two-way repeated measures ANOVA with
treatment as one factor, and time as the other factor,
after data transformation (inverse of the squared root).
The association between nominal variables was assessed
with the Chi-Square test with Yates’ correction or with
the Fisher test. The correlations between quantitative
variables were tested by Pearson’s coefficient and ana-
lyzed by simple linear regression. All p-values were cor-
rected with the Bonferroni adjustment in case of
multiple comparisons. The analyses were performed
with Prism 5.0 software (GraphPad, San Diego, CA)
and Stata Statistical Software Release 12 (StataCorp LP,
College Station, TX).Table 2 Variations of T-cell subpopulations after therapy with
HCa p
(HC vs. T0)
CD4+CD28neg (%) 3.6 (2.6-4.5) 0.996
CD4+CD28neg (cells/μL) 34 (22-78) 0.588
CD8 + CD28neg (%) 14.6 (7.3-23.1) <0.001
CD8+CD28neg (cells/μL) 53 (28-117) 0.072
CD4+CD45RA+CD31+ RTEd (%) 25.0 (20.6-25.8) 1.000
CD4+CD45RA+CD31+ RTE (cells/μL) 182 (138-202) 0.582
CD4+CD45RA+CCR7− (%) 0.9 (0.4-1.6) 0.164
CD4+CD45RA+CCR7− (cells/μL) 6 (5-11) 0.340
Data are expressed as median and IQR.
aHC: healthy controls; bT0: before ABA therapy; cT12: after 12 months of ABA therapResults
Phenotypic characterization of circulating T cells
The percentage and number of CD4+CD28neg T cells did
not differ between RA patients and HC before therapy
initiation, but the median percentage of these cells was
significantly reduced after 12 months of ABA (Table 2).
The percentage of CD4+CD28neg T cells decreased in
most patients, in some remained almost unchanged, and
increased in 8 patients (Figure 1). Also CD8+CD28neg T
cells, which were significantly higher in RA patients at
T0, significantly decreased at T12. The reduction of
CD28neg cell percentage in the CD4+ subset (Additional
file 1: Figure S1A), but not in the CD8+ counterpart,
correlated with the decrease in disease activity, assessed
by DAS28-CRP (r:0.43; p:0.045 and r:0.123; p:0.469).
The thymic output, measured by means of RTE levels,
was similar to that of HC before ABA therapy, and the
treatment did not significantly modify the proportion and
absolute number of these cells. Similarly, the percentage
and the absolute number of CD4+CD45RA+CCR7− highly
antigen-experienced T cells were not modified by the
treatment.
T-cell repertoire and TERT levels
TCRBV repertoire was analyzed in a subgroup of 17 pa-
tients, enrolled starting from November 2009, in whom
sufficient quality and quantity of biological material was
available. The minor differences found between these 17
patients and the entire cohort of enrolled patients
(Table 1) were likely due to the different use of ABA in
clinical practice during time. In fact, initially reserved
for patients resistant to other biological drugs, often
after multiple therapy failures, ABA was progressively
employed also as a second- or even first- line choice in
disease modifying anti-rheumatic drug-resistant patients.
Before therapy initiation, the median proportion of
TCRBV families with altered CDR3 (i.e. with shifted/
skewed, restricted or mono/oligoclonal distribution) wasABA and comparison with healthy controls
RA T0b RA T12c p
(RA T0 vs. RA T12)
5.0 (2.5-8.7) 1.6 (0.4-9.2) 0.032
35 (21-76) 15 (8-25) 0.096
39.4 (25.6-50.4) 27.8 (14.8-35.6) 0.012
96 (58-148) 44 (30-95) 0.006
18.4 (14-29.2) 19.3 (15.7-32.1) 1.000
155 (98-307) 226 (123-344) 1.000
2.1 (0.5-5.1) 0.9 (0.6-1.9) 0.076
13 (6-27) 9 (3-28) 0.132
y; dRTE: recent T emigrants.
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Figure 1 Percentage of CD4+CD28neg subset in ABA-treated
patients. CD4+CD28neg cell percentage analyzed before (T0) and
after 12 months of therapy with ABA.
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p < 0.0001] (Figure 2A), but significantly decreased after12
months of treatment, [70% (59–74%); p = 0.007]. The
same results were observed when the mean percentage of
all TCRBV chain perturbations of all patients were globally
analyzed (Figure 2B) and when TCRBV perturbations
were analyzed in individual RA patient by calculating the
difference between the alterations of CDR3 profiles ob-
served at T12 and at T0 (Figure 2C). Indeed, perturbations
decreased in most patients and in one of them (patient
#16), the reduction involved nearly all TCRBV chains. In
this patient a modification of altered CDR3 profile was
observed in 22 out the 23 TCRBV chains analyzed, that
acquired a nearly Gaussian-like (polyclonal) distribution
in the sample obtained at 12 months of ABA therapy
(Figure 3).
The lowering of TCRBV chain perturbations correlated
with the reduction of CD4+CD28neg subset percentage
(r:0.55; p:0.026; Additional file 1: Figure S1B), but not
with the changes of CD8+CD28neg or RTE percentages.
Analogously, the variations of TCRBV repertoire diver-
sity after therapy with ABA were not associated with age
and disease duration, with the presence of rheumatoidfactor, anti-cyclic citrullinated peptide antibodies, or
with a decrease of disease activity as measured by the
validated index DAS28-CRP.
The levels of TERT correlated with the average TCRBV
perturbation at T0 (r:0.72; p = 0.019), but no differences
were found between samples obtained before and after
ABA therapy [median NR: 66 (51-159) vs. 77 (32-183)].
Discussion
Herein we report that ABA treatment not only induces a
decrease of the CD28neg cell subsets, but also causes a
reduction of peripheral TCRBV oligoclonal cells that,
stably present in RA patients over long periods of time,
are considered of pathophysiologic relevance in this
disease [1,16].
The documented reduction of expanded clonotypes in
our patients was not related to an immune reconstitution
through a thymic output because newly produced T lym-
phocytes were equally represented before and after ABA
therapy. This is in agreement with data indicating that
ABA does not modify the level of interleukin-7 (IL-7),
which is known to stimulate the thymic output [17]. A
similar capacity to reduce clonal expansions of CD4+ T
cells was observed by Pierer et al [18] in 19 RA patients
treated with etanercept and in 9 with infliximab, two
tumor-necrosis factor alpha (TNFα) blocking agents.
The number of RTE was not directly evaluated by
Pierer at al [18], but since anti-TNFα therapy increased
the levels of IL-7, which is known to stimulate thymic
output of T cells as well as the expansion of naïve per-
ipheral T cells, the authors suggested that this might
contribute to the normalization of the TCR repertoire.
Of note, patient cells were phenotyped before anti-TNFα
treatment initiation and after 2, 4 and 12 months by flow
cytometry, but no significant changes in the percentage
of CD4+ CD28neg population were found [18].
To understand why T-cell repertoire could broaden
without a change in thymic production of T cells it must
be taken into account that thymic output is necessary
under lymphopenic conditions, when RTE can fill the
void and restore the compromised TCR repertoire [19].
When this is not the case, as in our ABA-treated pa-
tients, newly produced T lymphocytes may be not ac-
cepted into the periphery [19] and, therefore, RTE may
not be enriched in peripheral blood.
On the other hand, ABA-induced reduction of T-cell
expansion was not due to the restoration of the defective
telomerase activity that, demonstrated in naïve T cells of
RA patients, can result into an excessive induction of
apoptosis [11]. Indeed, an increased apoptosis may
undermine the homeostatic control of the T-cell com-
partment and set the stage for lymphopenia-induced re-
duction of T-cell repertoire diversity. On the contrary,
the correlation between TERT levels and the average
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Figure 2 Analysis of T-cell repertoire. TCRBV chain perturbations were determined by CDR3 spectratyping analysis in samples of RA patients,
obtained before (T0) and after 12 months (T12) of ABA therapy, and of healthy controls (HC). A. Mean percentage of normally distributed
polyclonal (≥7 peaks, Gaussian distribution), shifted/skewed (≥7 peaks, deviation from Gaussian distribution), restricted (≤ peaks 7, prominent
deviation from Gaussian distribution) or mono/oligoclonal expanded (1 or 2 dominant peaks) TCRBV chains. B. Average percentage of TCRBV
perturbations calculated with the generalized Hamming distance method [12]. Each symbol represents a subject’s overall TCRBV mean perturbation.
C. Detailed analysis of TCRBV perturbation decrease at the single patient level. For each TCRBV, the perturbation observed at T0 was subtracted from
that found at T12; when negative, this difference was coded as follows: white dots: 1-10% perturbation decrease; gray dots: 10- to -20% perturbation
decrease; black dots >20% perturbation decrease. *Number of TCRBV chains in which the perturbations at T12 were decreased over total number of
TCRBV chains analyzed.
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samples obtained before ABA initiation, supports the
hypothesis that high expression of telomerase coincides
with periods of T-cell expansion [20,21]. The absence of
TERT modifications after ABA therapy suggests that this
is not a relevant factor in the repertoire broadening and
other ways to reduce T-cell clonality may be operative. One
such alternative scenario would be that CD28neg cells need
regular TCR tuning for their survival and that ABA inter-
feres with this and some clones thereby disappear.
We have not found a correlation between TCR repertoire
modifications and disease activity variations, measured as
DAS28-CRP index, making unlikely an indirect effect of1 542 3 7 98 131211
TCRBV cha
6
Figure 3 Electropherograms obtained by CDR3 spectratyping analysi
before ABA initiations (A) and after 12 months of therapy (B). CDR3 size is
intensity) is shown on the y axis.reduced levels of inflammation on T-cell repertoire varia-
tions. Nevertheless, we cannot exclude a re-expression of
CD28 on memory clonal T cells after ABA therapy; in this
case variations on CD28-mediated trafficking of memory
T cells [22] might contribute to the reduction of memory
clonal populations in the peripheral blood.
The lack a control group such as RA patients treated
with other drugs exerting a similar effect on CD28neg
populations may be a limitation of the present study.
However, it should be considered that, for instance,
nonsteroidal anti-inflammatory drug, methotrexate and
two TNFα blocking agents, have not effect on these cells
[18,23].14 15 16 1817 20 22 23 252421
ins 
A
B
s of 23 TCRBV chains of RA patient #16. Samples were obtained
shown on the x axis, while the relative peak intensity (fluorescence
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Our data suggest that blocking CD28-costimulation
induces a reduction of peripheral blood T-cell expansions.
The same results have been observed in patient treated
with anti-TNFα [17], but the mechanism responsible for
the normalization of T-cell expansion seem to be different.
Indeed, in patients treated with ABA, the correlation of
the repertoire modifications with the reduction of the
CD4+CD28neg population suggests that the diminished
skewing of the repertoire is due to the decreased gener-
ation of these lymphocytes. This population consists
mainly of senescent, highly antigen-experienced cells,
largely overlapping with that displaying CD45RA+CCR7−
phenotype. The proinflammatory properties of CD4+CD28neg
cells (through γ-IFN production [23,24]), support
their potential pathogenic role in RA.
Additional file
Additional file 1: Figure S1. Correlation of variations of CD4+CD28neg
T cell percentage after 12 months of ABA treatment with variations of
DAS28-CRP (A) and with the mean TCRVB perturbation rate (B).
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